Abbott enters the field of electrophysiology through acquisition

Source: Xinkangjie, November 5, 2014 in recent years, the overall expansion of the medical device industry has slowed down, but some sub sectors such as electrophysiology have sprung up It is predicted that the annual growth rate of electrophysiology will reach 10% by 2020 This is why Abbott suddenly entered this field when its growth rate is far lower than the overall level of the industry Electrophysiological products refer to catheter installation equipment for the treatment of arrhythmia Abbott has made three deals in the industry, buying a start-up, getting a buy option from another start-up and investing in a venture Abbott is clear about its interest in the field of electrophysiology, but there is a long way to go to become a leading company in the industry Acquisition of topera Abbott to acquire topera medical for us $250 million to enter the field of electrophysiology Topera's technique is not to treat AF, but to diagnose it The company's 3D mapping system can diagnose spiral waves, which is one of the mechanisms by which arrhythmias spread Using topera's products to guide ablation of the heart, the success rate of the first operation was 87.5%, and 80.5% of patients did not need ablation after one year, according to a doctor initiated study According to topera, the success rate of catheter ablation alone was between 50% and 60% As a result, the technology could be out of the area that must be processed to speed up ablation, the company said Another company that Abbott is interested in is advanced cardiac therapeutics, a ablation catheter developer Abbott has obtained the option to purchase the company, and the specific price is not disclosed Abbott ventures, a venture capital firm owned by Abbott, also invested $32 million in vytronus In fact, as early as April 2013, Abbott ventures and new enterprise associates, another venture capital fund, jointly invested in topera Hot industry topera is a private company, so it will not disclose product sales data and changes For Abbott, it will not set up a new separate electrophysiology business unless the sales and growth rate of the electrophysiology business after acquisition are competitive According to evaluatemedtech, the global electrophysiological market is growing at a double-digit rate, and almost every company in this field is growing The only exception is C.R bard, which last summer sold almost all of its ablation products to Boston Scientific for $275 million The market leader in electrophysiology is BioSense Webster, a Johnson & Johnson ablation business Last year, BioSense Webster was the only company in the industry with annual revenue of more than $1 billion, followed by St Jude Medical with annual sales of $957 million The two companies are long-term rivals Although BioSense is not easy to beat Saint Juda, the gap between the two is expected to narrow to within 200 million US dollars by 2020 The fastest growing company in the field of electrophysiology is China's minimally invasive medicine, with a growth rate of 20%, but its starting point is relatively low Abbott hopes to enter the field of electrophysiology and promote its vascular products business The business is expected to grow by just 3% by 2020 If topera's technology is successful, Abbott may then choose to buy advanced cardiac therapeutics, or even vytronus